Researchers are zeroing in on understanding what goes awry in the brains of people with Alzheimer’s disease.
Tek Image/Science Photo Library via Getty Images
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease.
Kateryna Kon/Science Photo Library via Getty Images
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Do the benefits of approving a drug before confirming it works outweigh the potential costs?
monkeybusinessimages/iStock via Getty Images Plus
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.